Cure Vac N.V. CVAC
We take great care to ensure that the data presented and summarized in this overview for CureVac N.V. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding CVAC
View all-
Israel Englander Millennium Management LLC | New York, Ny2.42MShares$6.05 Million0.0% of portfolio
-
Black Rock Inc. New York, NY2.25MShares$5.63 Million0.0% of portfolio
-
Bill & Melinda Gates Foundation Seattle, WA1.57MShares$3.92 Million10.6% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il1.01MShares$2.53 Million0.0% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct780KShares$1.95 Million0.01% of portfolio
-
Alyeska Investment Group, L.P. Chicago, IL400KShares$1 Million0.01% of portfolio
-
Goldman Sachs Group Inc New York, NY373KShares$932,2950.0% of portfolio
-
Dz Bank Ag Deutsche Zentral Genossenschafts Bank, Frankfurt Am Main Frankfurt Am Main, 2M284KShares$708,9370.0% of portfolio
-
Ubs Asset Management Americas Inc Chicago, IL277KShares$692,9150.0% of portfolio
-
Geode Capital Management, LLC Boston, MA219KShares$548,1470.0% of portfolio
Latest Institutional Activity in CVAC
Top Purchases
Top Sells
About CVAC
CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202, a prophylactic mRNA-based vaccine, which has completed Phase 1 clinical trial for rabies virus glycoprotein; and CVSQIV, which is in Phase 1 clinical trial against influenza, as well as vaccine for lassa fever, yellow fever, respiratiory syncytial virus, rotavirus, malaria, and universal influenza. The company also develops RNA-based cancer immunotherapies, including CV8102, which is in Phase 1 clinical trial for treating cutaneous melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck. The company was founded in 2000 and is headquartered in Tübingen, Germany.
Insider Transactions at CVAC
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|